Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. MyoKardia, Inc.
  6. Summary
    MYOK   US62857M1053

MYOKARDIA, INC.

(MYOK)
 SummaryChartsNewsRatingsCompany 
Quotes 5-day view   End-of-day quote. End-of-day quote Nasdaq
03/25/2020 03/26/2020 03/27/2020 03/30/2020 03/31/2020 Date
49.56 53.07 53.42 51.4 46.88 Last
717700 516851 396351 387235 923416 Volume
+2.23% +7.08% +0.66% -3.78% -8.79% Change
Company
MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an... 
More about the company
Ratings of MyoKardia, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about MYOKARDIA, INC.
02/23Bristol Myers Squibb and Celgene Issue Notices of Redemption and Partial Rede..
AQ
02/04BRISTOL MYERS SQUIBB  : Posts 4Q Adjusted Profit, Growth for Eliquis, Opdivo
DJ
01/11Bristol Myers sees up to $25 billion a year of new revenue from current drug ..
RE
2020BRISTOL MYERS SQUIBB  : Completes Acquisition of MyoKardia, Strengthening Compan..
AQ
2020MYOKARDIA, INC.  : Termination of a Material Definitive Agreement, Completion of..
AQ
2020MYOKARDIA  : Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM Study of Ma..
AQ
2020MYOKARDIA  : Presents Mavacamten Clinical and Non-Clinical Data at the American ..
AQ
2020MYOKARDIA  : Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM Study of Ma..
AQ
2020MyoKardia Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM Study of Ma..
GL
2020MYOKARDIA  : Presents Mavacamten Clinical and Non-Clinical Data at the American ..
AQ
2020MyoKardia Presents Mavacamten Clinical and Non-Clinical Data at the American ..
GL
2020MYOKARDIA  : Collaborates with the American College of Cardiology and PINNACLE/V..
AQ
2020MyoKardia Collaborates with the American College of Cardiology and PINNACLE/V..
GL
2020MYOKARDIA : 3Q Earnings Snapshot
AQ
2020MYOKARDIA  : Management's Discussion and Analysis of Financial Condition and Res..
AQ
More news
News in other languages on MYOKARDIA, INC.
02/04US-Pharmakonzern Bristol-Myers wird trotz Quartalsverlusts zuversichtlicher
2020TOUR D’HORIZON DES INDICES  : deux indices très “rotation sectorielle”
2020Des idées d'ETF pour miser sur le retour en grâce des valeurs moyennes
2020Aktien New York Schluss: Trump-Erholung sorgt für starken Wochenauftakt
2020Aktien New York: Gewinne - Nachlassende Unsicherheit dank Trump-Genesungsproz..
More news
Analyst Recommendations on MYOKARDIA, INC.
More recommendations
Chart MYOKARDIA, INC.
Duration : Period :
MyoKardia, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
NameTitle
Anastasios E. Gianakakos Chief Executive Officer
Elizabeth Mily President & Director
Robert Scott McDowell Chief Scientific Officer
Jay Edelberg Senior Vice President-Clinical Development
Jeffrey Galik Treasurer, Director & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
MYOKARDIA, INC.0.00%11 993
GILEAD SCIENCES, INC.16.98%85 472
WUXI APPTEC CO., LTD.30.07%66 801
REGENERON PHARMACEUTICALS9.45%54 755
BIONTECH SE170.58%53 275
VERTEX PHARMACEUTICALS-17.58%50 427